Defective HEXA does not cleave the terminal GalNAc from keratan sulfate

Stable Identifier
Reaction [transition]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Beta-hexosaminidase A (HEXA) cleaves the terminal N-acetyl galactosamine (GalNAc) from glucosaminoglycans (GAGs) and any other molecules containing a terminal GalNAc. Defects in the alpha subunits are the cause of GM2-gangliosidosis type 1 (GM2G1; MIM:272800), also known as Tay-Sachs disease (Nakano et al. 1988). The severest form of Tay-Sachs disease, infant-onset, is characterised by neurodegeneration, blindness and death by age 2 or 3. Hexosaminidase activity in this form of the disease is below 10% of normal levels (Okada et al. 1971). The most frequent mutation of infant-onset Tay-Sachs disease of Ashkenazi Jews is a 4-bp insertion in exon 11. This mutation introduces a premature termination signal (p.Y427Ifs*5) resulting in a deficienct mRNA (Myerowitz & Costigan 1988).

More than 100 mutations in HEXA have been identified to date with varying severity of disease. The next most common mutation produces abnormally processed RNA; a G to C transversion at the 5' end of intron 12 (Arpaia et al. 1988, Myerowitz 1988) (not annotated here). This mutation, together with Y427Ifs*5, account for ~97% of the HEXA gene mutations in the Ashkenazi Jewish population (Mahuran 1995).

Participant Of
Catalyst Activity
Catalyst Activity
beta-N-acetylhexosaminidase activity of HEXA Y427Ifs*5 [lysosomal lumen]
Physical Entity
Normal reaction
Name Identifier Synonyms
gangliosidosis GM1 3322 GM1 gangliosidosis (disorder), GM>1< gangliosidosis (disorder), beta-Galactosidase deficiency, deficiency of beta-galactosidase (disorder), Beta-galactosidase deficiency, Landing syndrome
Cite Us!